• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by NeOnc Technologies Holdings Inc.

    5/15/26 4:59:25 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NTHI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    NEONC TECHNOLOGIES HOLDINGS, INC.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)




    64051A101

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    64051A101


    1Names of Reporting Persons

    Cinctive Capital Management LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,483,980.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,483,980.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,483,980.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IA, PN

    Comment for Type of Reporting Person:  See disclosure in Item 4


    SCHEDULE 13G

    CUSIP Number(s):
    64051A101


    1Names of Reporting Persons

    Cinctive GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,483,980.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,483,980.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,483,980.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO, HC

    Comment for Type of Reporting Person:  See disclosure in Item 4


    SCHEDULE 13G

    CUSIP Number(s):
    64051A101


    1Names of Reporting Persons

    Richard H. Schimel
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,483,980.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,483,980.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,483,980.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IN, HC

    Comment for Type of Reporting Person:  See disclosure in Item 4


    SCHEDULE 13G

    CUSIP Number(s):
    64051A101


    1Names of Reporting Persons

    Lawrence J. Sapanski
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,483,980.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,483,980.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,483,980.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IN, HC

    Comment for Type of Reporting Person:  See disclosure in Item 4


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    NEONC TECHNOLOGIES HOLDINGS, INC.
    (b)Address of issuer's principal executive offices:

    23975 Park Sorrento, Suite 205, Calabasas, California, 91302
    Item 2. 
    (a)Name of person filing:

    This Statement is filed on behalf of each of (i) Cinctive Capital Management LP, (ii) Cinctive GP LLC, the general partner of Cinctive Capital Management LP, and (iii) Richard H. Schimel and Lawrence J. Sapanski, the co-founders and co-Chief Investment Officers of Cinctive Capital Management LP and managing members of Cinctive GP LLC (collectively, the "Reporting Persons").
    (b)Address or principal business office or, if none, residence:

    The address of each Reporting Person is 50 Hudson Yards, 67th Floor, New York, NY 10001.
    (c)Citizenship:

    Cinctive Capital Management LP is a Delaware limited partnership. Cinctive GP LLC is a Delaware limited liability company. Richard H. Schimel and Lawrence J. Sapanski are citizens of the United States.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP Number(s):

    64051A101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of March 31, 2026, each of the Reporting Persons may be deemed the beneficial owner of 2,483,980 shares of Common Stock, which amount consists of 1,425,526 shares of Common Stock and 1,058,454 shares of Common Stock that the Reporting Persons have the right to acquire upon exercise of Warrants, subject to the Blocker (as defined herein). The Issuer shall not effect any exercise of the Warrants, and the Reporting Persons shall not have the right to exercise any portion of the Warrants, to the extent that after giving effect to such issuance after exercise, the Reporting Persons (together with the Reporting Persons' affiliates, and any other persons or entities acting as a group together with the Reporting Persons or any of the Reporting Persons' affiliates), would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of Warrants, subject to a potential increase provided that any increase will not be effective until the 61st day after the Reporting Persons deliver notice of such increase to the Issuer (the "Blocker").
    (b)Percent of class:

    As of March 31, 2026, each of the Reporting Persons may be deemed the beneficial owner of approximately 9.99% of the shares of Common Stock outstanding. This percentage is based on (i) 23,806,216 shares of Common Stock outstanding as of March 30, 2026, as reported in the Issuer's annual report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2026, and (ii) 1,058,454 shares of Common Stock issuable to the Reporting Persons within 60 days upon exercise of Warrants, subject to the Blocker, which shares of Common Stock have been added to the total shares of Common Stock outstanding in accordance with Rule 13d-3(d)(1)(i) under the Securities Exchange Act of 1934, as amended.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    2,483,980

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    2,483,980

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See disclosure in Items 2 and 4 hereof. Cinctive Global Master Fund, Ltd has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the shares of Common Stock covered by this statement that may be deemed to be beneficially owned by the Reporting Persons.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See disclosure in Item 2 hereof.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Cinctive Capital Management LP
     
    Signature:/s/ Richard H. Schimel
    Name/Title:Richard H. Schimel, Managing Member of Cinctive GP LLC, its General Partner
    Date:05/15/2026
     
    Cinctive GP LLC
     
    Signature:/s/ Richard H. Schimel
    Name/Title:Richard H. Schimel, Managing Member
    Date:05/15/2026
     
    Richard H. Schimel
     
    Signature:/s/ Richard H. Schimel
    Name/Title:Richard H. Schimel
    Date:05/15/2026
     
    Lawrence J. Sapanski
     
    Signature:/s/ Lawrence J. Sapanski
    Name/Title:Lawrence J. Sapanski
    Date:05/15/2026
    Exhibit Information

    Exhibit 1: Joint Filing Agreement

    Get the next $NTHI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NTHI

    DatePrice TargetRatingAnalyst
    5/19/2026$13.00Buy
    Alliance Global Partners
    5/18/2026$20.00Buy
    Maxim Group
    4/24/2026$15.00Buy
    BTIG Research
    More analyst ratings

    $NTHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Heshmatpour Amir F bought $41,592 worth of shares (10,000 units at $4.16), increasing direct ownership by 0.33% to 3,072,000 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    5/4/26 2:08:58 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Heshmatpour Amir F bought $45,180 worth of shares (10,000 units at $4.52), increasing direct ownership by 0.33% to 3,062,000 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    4/28/26 6:00:05 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Clinical Officer Neman-Ebrahim Yousha bought $2,440 worth of shares (500 units at $4.88), increasing direct ownership by 0.37% to 134,760 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    4/24/26 6:10:07 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Multi-Billion-Dollar Search for Better Glioblastoma Treatments

    DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. Yet one of oncology's greatest challenges remains largely unsolved. Glioblastoma. Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with the difficulty of delivering therapies into the brain, has mad

    6/3/26 9:28:24 AM ET
    $BNTX
    $IBRX
    $KZIA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode

    DENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Eli Lilly (NYSE:LLY) has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer. The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary Session at the 2026 ASCO Annual Meeting and will be simultaneously published in The New England Journal of Medicine. For investors, the

    6/1/26 9:05:00 AM ET
    $LLY
    $NTHI
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Next Great AI Revolution May Be Drug Delivery

    DENVER, May 29, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – When most investors think about artificial intelligence, they picture chatbots, automation platforms, semiconductors, or cloud infrastructure. Yet some of the most important long-term applications of AI may ultimately emerge inside healthcare, particularly in the development and delivery of advanced therapeutics. The biotechnology sector is rapidly entering a new era where AI is no longer just helping discover drugs, it is beginning to reshape how therapies are delivered, personalized, monitored, and commercialized. This shift could become most important in diseases involving the brain and central nervous system. That is

    5/29/26 9:05:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    SEC Filings

    View All

    NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

    5/18/26 5:00:15 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by NeOnc Technologies Holdings Inc.

    SCHEDULE 13G - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Subject)

    5/15/26 4:59:25 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by NeOnc Technologies Holdings Inc.

    10-Q - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

    5/15/26 4:32:11 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on NeOnc Technologies Holdings with a new price target

    Alliance Global Partners initiated coverage of NeOnc Technologies Holdings with a rating of Buy and set a new price target of $13.00

    5/19/26 8:31:51 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on NeOnc Technologies Holdings with a new price target

    Maxim Group initiated coverage of NeOnc Technologies Holdings with a rating of Buy and set a new price target of $20.00

    5/18/26 8:44:12 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on NeOnc Technologies Holdings with a new price target

    BTIG Research initiated coverage of NeOnc Technologies Holdings with a rating of Buy and set a new price target of $15.00

    4/24/26 8:06:10 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Heshmatpour Amir F bought $41,592 worth of shares (10,000 units at $4.16), increasing direct ownership by 0.33% to 3,072,000 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    5/4/26 2:08:58 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Heshmatpour Amir F bought $45,180 worth of shares (10,000 units at $4.52), increasing direct ownership by 0.33% to 3,062,000 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    4/28/26 6:00:05 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Clinical Officer Neman-Ebrahim Yousha bought $2,440 worth of shares (500 units at $4.88), increasing direct ownership by 0.37% to 134,760 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    4/24/26 6:10:07 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    Leadership Updates

    Live Leadership Updates

    View All

    NeOnc Technologies Appoints David Choi as Chief Accounting Officer

    CALABASAS, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, has appointed David Choi as Chief Accounting Officer. In this role, Mr. Choi is responsible for overseeing the Company's accounting, financial reporting, internal controls, and corporate governance functions as NeOnc advances its clinical-stage biotechnology platform and expands its global operations. "David's extensive expertise in technical accounting and financial reporting for public companies comes at a pivotal time for NeOnc," said

    3/13/26 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Appoints Amir Heshmatpour as Chief Executive Officer to Drive Next Phase of Clinical and Corporate Growth

    CALABASAS, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced that its Board of Directors has appointed Amir Heshmatpour as Chief Executive Officer. Mr. Heshmatpour, who was appointed President in April, will assume the CEO role effective immediately, continuing to serve as Executive Chairman of the Board. Dr. Thomas Chen, the company's founder, will transition from the CEO role to focus exclusively on his positions as Chief Medical Officer, Chief Scientific Officer, and member of the Board of Di

    11/4/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board

    CALABASAS, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. David M. Ashley to its scientific advisory board. Dr. Ashley is the Rory David Deutsch Distinguished Professor of Neuro-Oncology and the Director of The Preston Robert Tisch Brain Tumor Center at Duke University. Amir F. Heshmatpour, Executive Chairman & President, of NeOnc Technologies, commented, "We are privileged to have Dr. David M. Ashley MBBS (Hons), FRACP, PhD, of Duke University on NeOnc's Scientific Adv

    10/2/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    Financials

    Live finance-specific insights

    View All

    NeOnc Provides Business Update and Reports Q1 2026 Financial Results

    CALABASAS, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company advancing two Phase 2 programs in central nervous system (CNS) cancers, today announced financial results for the first quarter ended March 31, 2026, and provided an update on recent operational achievements and upcoming milestones. Amir Heshmatpour, Chief Executive Officer, Executive Chairman, and President, commented: "The first quarter of 2026 marked a transformational period for NeOnc as we advanced both of our lead clinical programs toward important regulatory and value-creation milestones. We successfully comp

    5/18/26 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

    CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced data from the dose-escalation portion of its Phase 1/2 clinical trial for NEO212, the Company's novel oral bio-conjugated therapy and will host a conference call to discuss the data today at 9:00am ET. NeOnc has formally notified the FDA that the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial has reached Maximum Tolerated Dose (MTD) at Cohort 5 (810 mg, Days 1–5, 28-day cycle) following a second

    3/4/26 8:00:00 AM ET
    $MRK
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity

    CALABASAS, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced today announced that it will host an investor conference call and webcast on March 4, 2026, at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time. During the call, members of the NeOnc management team and independent members of the Company's Scientific Advisory Board (SAB) will present initial data from the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial, evaluating NeOnc's proprietary bioconjugated

    2/27/26 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care